Bearish Analysts Bombard Battered Pharma Stock

LifeSci Capital called ACER a "high-risk investment"

by Karee Venema

Published on Jun 26, 2019 at 9:52 AM

Acer Therapeutics Inc (NASDAQ:ACER) plunged 78.6% yesterday -- its worst session since September 2008 -- after the Food and Drug Administration (FDA) failed to approve the firm's rare genetic disorder treatment, requesting new clinical data. ACER shares are lower again today, last seen down 4.6% at $3.93, as bearish analysts blast the crumbling pharma stock.

For starters, Raymond James downgraded ACER stock to "market perform" from "outperform." H.C. Wainwright, meanwhile, slashed its price target to $10 from $55. Plus, LifeSci Capital called Acer Therapeutics a "high-risk investment," and that failure to gain regulatory approval or positive data from the "upcoming bioequivalence study could adversely affect Acer's stock price."

There's certainly room for more downgrades and/or price-target cuts to come through. While three of six analysts maintain a "buy" or better rating on ACER stock -- and not a single "sell" on the books -- the average 12-month price target of $9 is a roughly 128% premium to current trading levels.

Elsewhere on the sentiment front, short sellers have certainly set their sights on an attractive target. Short interest jumped almost 71% in the two most recent reporting periods to 307,617 shares. These bears are sidelined through today's trading, considering ACER stock found a spot on the short-sale restricted list amid yesterday's sell-off.


A Schaeffer's exclusive

TOP STOCK PICKS 2020

Access your FREE insider report before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Security Stock Targeting Terrorism
Click to continue to advertiser's site.
Earnings, China Deal Signing Guides Stocks to Fresh Highs
Traders were greeted with some M&A buzz, too
Twitter Stock Drops on Analyst Slam
TWTR has been attempting to recover from its fourth-quarter lows
The Security Stock Targeting Terrorism
Click to continue to advertiser's site.